Zilovertamab is a Monoclonal Antibody owned by Oncternal Therapeutics, and is involved in 8 clinical trials, of which 3 were completed, and 5 are ongoing.

Zilovertamab (UC-961) works by targeting the cancer cells which express receptor tyrosine kinase-like orphan receptor 1 (ROR1). This protein is highly expressed during embryonic development of various tumors. The antibody with the help from immune system targets ROR1 and induces T cell response to exert its cytotoxic effect against the tumor cells expressing this antigen.

The revenue for Zilovertamab is expected to reach a total of $264m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zilovertamab NPV Report.

Zilovertamab was originated by University of California San Diego and is currently owned by Oncternal Therapeutics.

Zilovertamab Overview

Zilovertamab (UC-961) is under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, marginal zone b-cell lymphoma, metastatic castration resistant prostate cancer, relapsed or refractory diffuse large B-cell lymphoma, metastatic or locally advanced unresectable triple negative breast cancer, HER2 negative breast cancer and mantle cell leukemia. The therapeutic candidate is administered intravenously and it acts by targeting ROR1. It was under development for ovarian cancer.

Oncternal Therapeutics Overview

Oncternal Therapeutics (Oncternal), formerly GTx, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$4.3 million for the fiscal year ended December 2021 (FY2021), an increase of 27.9% over FY2020. The operating loss of the company was US$31.4 million in FY2021, compared to an operating loss of US$17.5 million in FY2020. The net loss of the company was US$31.3 million in FY2021, compared to a net loss of US$17.2 million in FY2020. The company reported revenues of US$0.4 million for the third quarter ended September 2022, an increase of 100% over the previous quarter.

Quick View – Zilovertamab

Report Segments
  • Innovator
Drug Name
  • Zilovertamab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.